Journal of Clinical Oncology, Vol 18, Issue 3
(February), 2000: 562
© 2000 American Society for Clinical Oncology
Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients
By J. Alexandre,
P. Bleuzen,
J. Bonneterre,
W. Sutherland,
J. L. Misset,
J.-P. Guastalla,
P. Viens,
S. Faivre,
A. Chahine,
M. Spielman,
A. Bensmaïne,
M. Marty,
M. Mahjoubi,
E. Cvitkovic
From the Paul Brousse Hospital and Institut Gustave Roussy, Villejuif; Cvitkovic & Associés Consultants, Kremlin-Bicêtre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre Léon Bérard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rhône-Poulenc Rorer, Montrouge, France.
Address reprint requests to Esteban Cvitkovic, MD, Hôpital Paul Brousse,12 Avenue Paul Vaillant Couturier, 94804 Villejuif Cedex, France; email e.cvitkovic{at}cvitkovic-ac.fr
PURPOSE: To identify predictive factors for efficacy and safety in advanced breast cancer (ABC) patients treated in the French compassionate-use docetaxel program.
PATIENTS AND METHODS: A total of 825 ABC patients treated with docetaxel (100 mg/m2 every 3 weeks) were source-reviewed and analyzed for prognostic factors associated with overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), febrile neutropenia, mucositis, and severe fluid retention syndrome by univariate and multivariate analysis.
RESULTS: The ORR was 22.9% (95% confidence interval, 20.2% to 26.2%). The median TTF and OS were 4.0 and 9.8 months, respectively. By multivariate analysis, secondary anthracycline-resistant disease was significantly associated (P < .05) with lower ORR and shorter TTF and OS, whereas anthracycline-refractory disease was associated with shorter OS. Poor performance status was associated with lower ORR, shorter TTF, and shorter OS. Liver dysfunction (transaminase levels > 1.5 times the upper limit of normal [ULN] and alkaline phosphatase [AP] level > three times ULN) and time since first relapse less than 24 months were associated with shorter TTF and OS. Other significant correlations included the following: elevated CA 15-3 serum level with lower ORR; more than two involved sites, and minor transaminase and AP level abnormalities with shorter OS; and no previous chemotherapy for ABC with shorter TTF. According to multivariate analysis, ORR, TTF, and OS were not decreased in patients with liver metastases but without liver dysfunction.
CONCLUSION: Docetaxel activity was maintained in heavily pretreated ABC patients and in those with liver metastasis; docetaxel must be used cautiously, however, in patients with liver dysfunction in whom high morbidity risk necessitates strict adherence to dose-adaptation guidelines.
This article has been cited by other articles:
|
|
|
|
 
S. Buchholz, A. V. Schally, J. B. Engel, F. Hohla, E. Heinrich, F. Koester, J. L. Varga, and G. Halmos
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel
PNAS,
February 6, 2007;
104(6):
1943 - 1946.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Alexandre, E Rey, V Girre, S Grabar, A Tran, V Montheil, F Rabillon, V Dieras, V Jullien, P Herait, et al.
Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study
Ann. Onc.,
January 1, 2007;
18(1):
168 - 172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Gelmon, A. Chan, and N. Harbeck
The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer
Oncologist,
September 1, 2006;
11(suppl_1):
42 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rogatko, J. S. Babb, H. Wang, M. J. Slifker, and G. R. Hudes
Patient Characteristics Compete with Dose as Predictors of Acute Treatment Toxicity in Early Phase Clinical Trials
Clin. Cancer Res.,
July 15, 2004;
10(14):
4645 - 4651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. R. Mitchell, R. Basser, M. Chipman, A. Grigg, J. Cebon, I. D. Davis, J. Zalcberg, S. Ng, F. Appia, and M. Green
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours
Ann. Onc.,
May 1, 2003;
14(5):
788 - 794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Alexandre, M. Gross-Goupil, B. Falissard, M.-L. Nguyen, J.-M. Gornet, J.-L. Misset, and F. Goldwasser
Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy
Ann. Onc.,
January 1, 2003;
14(1):
36 - 41.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ali, K. Leitzel, V. M. Chinchilli, L. Engle, L. Demers, H. A. Harvey, W. Carney, J. W. Allard, and A. Lipton
Relationship of Serum HER-2/neu and Serum CA 15-3 in Patients with Metastatic Breast Cancer
Clin. Chem.,
August 1, 2002;
48(8):
1314 - 1320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L de Lemos and R. K O'Brien
Development of a pharmacist-coordinated system of chemotherapy protocols in an integrated healthcare delivery organization
Journal of Oncology Pharmacy Practice,
June 1, 2002;
8(2-3):
39 - 48.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Aihara, Y. Kim, and Y. Takatsuka
Phase II study of weekly docetaxel in patients with metastatic breast cancer
Ann. Onc.,
February 20, 2002;
13(2):
286 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wilson-Royalty, G. Lawless, C. Palmer, and R. Brown
Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature
Journal of Oncology Pharmacy Practice,
December 1, 2001;
7(4):
141 - 147.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Taamma, J. L. Misset, M. Riofrio, C. Guzman, E. Brain, L. Lopez Lazaro, H. Rosing, J. M. Jimeno, and E. Cvitkovic
Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors
J. Clin. Oncol.,
March 1, 2001;
19(5):
1256 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
